Switching Immunotherapy On Only Where It Matters: A Smarter Path to Safer Cancer Treatment

Taiwan Researchers Develop Smarter Cancer Immunotherapy That Targets Tumors While Sparing Healthy Organs

6-Feb-2026 4:25 AM EST, by iGroup

Newswise — Immune checkpoint inhibitors have reshaped cancer treatment worldwide by enabling the immune system to recognize and attack tumors. Yet despite their clinical and commercial success, their real-world impact remains constrained. For several widely used immunotherapies, response rates can be as low as 15–25%, and up to 80% of patients eventually discontinue treatment due to limited effectiveness or severe immune-related side effects. These toxicities arise largely because current therapies activate the immune system throughout the body rather than just at the tumor site. 

A research team at Kaohsiung Medical University (KMU), Taiwan, led by Professor Chuang Chih-Hung, has developed a new approach to overcome both challenges simultaneously: improving treatment efficacy while reducing harm to healthy tissues. Their solution is a tumor-selective “pro-immunocytokine” that combines an immune checkpoint inhibitor with interferon, a potent immune signaling molecule. 

The novelty of this strategy lies in how the therapy is activated. Instead of stimulating the immune system systemically, the engineered drug remains largely inactive in the bloodstream. It is activated only after it reaches the tumor microenvironment, where cancer-associated enzymes cleave the molecule, releasing its active components. Once activated locally, interferon increases the tumor’s visibility to immune cells, while the checkpoint inhibitor lifts immune suppression - focusing the immune response precisely where cancer cells reside. 

While researchers in the United States and Europe have explored combining cytokines with immune checkpoint inhibitors, most existing approaches rely on systemic administration. These approaches resulted in high toxicity, with more than 40% of patients in some trials requiring dose reduction or treatment discontinuation. By contrast, the KMU team’s enzyme-activated design introduces a level of spatial control that remains rare among current immunotherapy platforms. 

In preclinical studies, the tumor-activated therapy reduced tumor size by approximately 50%, enhanced immune activity within tumors by 4- to 8-fold, and reduced organ damage by approximately 75% compared with conventional treatment approaches. The platform has also shown compatibility with more than nine clinically used antibody drugs, suggesting broad applicability across multiple cancer types, including so-called “immune-cold” tumors that respond poorly to existing therapies. 

This research highlights Taiwan’s growing role in advancing cancer therapies that aim to improve patient safety, treatment effectiveness, and access to care. To learn more, readers are invited to explore the full press release and watch the accompanying research video. 

Original Link: https://www.newswise.com/articles/switching-immunotherapy-on-only-where-it-matters-a-smarter-path-to-safer-cancer-treatment